Abstract: A pharmaceutical preparation comprising:(a) isosorbide dinitrate as active ingredient(b) a solvent for isosorbide dinitrate(c) an ointment consistency agent(d) an emulsifying agent(e) water, and(f) possibly customary preservatives, antioxidants, buffers and/or odorants;where the weight ratio of water: consistency agent including emulsifying agent: solvent is 30 to 80: 3 to 35: 3 to 35, the amount of emulsifying agent is from 0% to 15% by weight and the amount of isosorbide dinitrate is from 2% to 20% by weight. The preparation has an ointment-like consistency and is administered topically to the skin, where it has a high adsorption rate and a long duration of response.

Abstract: Stable aqueous injectable solutions comprising alloxan stabilized with a reducing sugar selected from the group consisting of levulose, glucose and lactose are disclosed.

Abstract: The cholesterol blood level is lowered by administration of a spirogermanium (dimethyl, diethyl, dipropyl or dibutyl, diethyl or dibutyl being preferred).

Abstract: Certain known pyrimido[2,1-a]isoindoles and diazepino[2,1-a]isoindoles, e.g., 7-(p-chlorophenyl)-7-hydroxy-2,3,4,5-tetrahydro-7H-[1,3]-diazepino[2,1-a]i soindoles, are useful for inhibiting prolactin secretion.

Abstract: A rodenticide composition is provided comprising a dry mixture of a first ingredient which is a substance that rodents are fond of eating, and a second ingredient which has the propensity to react with water and thereby transform to a hydrated cementitious solid aggregate. Each of said ingredients is present to the extent of between about 20% and 60% by volume of said composition.A method of killing rodents is provided comprising disposing quantities of said composition in a manner to avoid contact with water in locations frequented by rodents, and allowing said rodents to ingest effective amounts of said composition.

Abstract: A process for controlling hypertension employing N-(substituted-phenyl)-N'-(1,4,5,6-tetrahydroprimidin-2-yl)ureas, and pharmaceutical compositions containing said ureas is described.

Abstract: The invention relates to a process for concentrating blood coagulation Factor XIII (Fibrin stabilizing factor) which comprises removing a fraction precipitated at a pH of 6 to 9 in a concentration of 4 to 9% (W/V) of an alkylenoxide polymer or copolymer having a molecular weight of 2,000 to 20,000 from a crude globulin fraction obtained from human placentae by separating in albumin fraction therefrom, and then collecting the fraction precipitated in the concentration of 20 to 30% (W/V) of said polymer or copolymer, thereby obtaining easily said blood coagulation Factor XIII free from pyrogen in good yield.

Abstract: Biosynthesis of triglycerides is inhibited by certain N-.beta.-phenethyl-N-pyridylalkylamines.

Abstract: A process for controlling waste nitrogen accumulation diseases in humans which comprises administering an effective amount of at least one compound selected from the group consisting of benzoic acid, phenylacetic acid and the non-toxic, pharmaceutically-acceptable salts of the acids to a human suffering from waste nitrogen accumulation.

Abstract: Novel treatments are disclosed for increasing circulating coronary blood flow. These treatments are useful for individuals who are expected to otherwise exhibit symptoms of reduced coronary circulation. Such individuals include those having coronary artery disease, angina, particularly unstable angina and Prinzmetal's angina, and coronary vasospasm. In accordance with the disclosed methods, coronary vasodilation is accomplished through the administration of effective amounts of buiprofen and/or flurbiprofen. At the indicated dosages, thromboxane synthesis is effectively inhibited without inhibiting prostacyclin synthesis. Flurbiprofen administration additionally results in thromboxane antagonism.

Abstract: Certain N-phenethylaminopropiophenones inhibit lipogenesis in mammals.

Abstract: Certain N-phenethylaminopropiophenones inhibit lipogenesis in mammals.

Abstract: Biosynthesis of triglycerides is inhibited by certain N-.beta.-phenethyl-N-thienylalkylamines.

Abstract: A water-soluble biotin-containing preparation prepared by spray-drying an aqueous solution comprising biotin and lactose with ammonia to obtain dried particles. Biotin in this preparation is highly soluble in water.

Abstract: Certain N-phenethylaminopropiophenones inhibit lipogenesis in mammals.

Abstract: The present invention is related to a process for the lowering of increased cholesterol and/or increased neutral fat levels in the blood of humans by administering to such humans a completely acetylated monoglyceride having the general formula ##STR1## wherein one of the groups R.sub.1, R.sub.2 and R.sub.3 is the acyl radical of a fatty acid having from 12 to 22 carbon atoms while the other two groups represent acetyl groups, or a mixture of several such completely acetylated monoglycerides, preferably orally and in a daily dosage ranging from 1 to 15 cc. of the pure acetylated monoglyceride or mixture of such acetylated monoglycerides, either in pure form or together with usual pharmaceutical carriers or diluents, possibly together with other lipid lowering agents, or incorporated in dietetic food products.

Abstract: Certain heterocyclyl 2-(2-(4-hydroxyphenyl)-2-hydroxy-1-methyl)ethylamino)ethyl ketones inhibit lipogenesis in mammals.

Abstract: The risk of ventricular fibrillation in animals is reduced by administering tyrosine, a tyrosine precursor, threonine or mixtures thereof, either alone or in combination with a substance which is known to reduce the risk of ventricular fibrillation. A novel composition is provided comprising a unit dosage form of tyrosine, a precursor for tyrosine, threonine or mixtures thereof and a substance which is known to reduce the risk of ventricular fibrillation.

Abstract: The present application relates to the treatment of hyperuricemias, including the prevention and treatment of gout, using the compound Itanoxone or a pharmaceutically-acceptable salt thereof. The compound Itanoxone has the chemical name 2'-chloro-4,4-biphenyl-4-oxo-2-methylene-butyric acid, and may alternatively be named 2-methylene 4-oxo 4-(4'-ortho-chlorophenylphenyl)-butyric acid. The formula for the compound is as follows: ##STR1##The international common name of this compound is "Itanoxone". Pharmaceutical compositions of the active ingredient, suitable for carrying out the method of the invention, and combinations thereof with other active ingredients, particularly colchicine and allopurinal, are also disclosed.

Abstract: 2-Fluoronorepinephrine has been found to have antihypertensive activity when orally administered to warm-blooded animals.